Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04425018
Title MARGetuximab Or Trastuzumab (MARGOT) (MARGOT)
Acronym MARGOT
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Georgetown University Medical Center Washington District of Columbia 20007 United States Details
MedStar Washington Hospital Center Washington District of Columbia 20010 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Dana-Farber Brigham Cancer Center - Foxborough Foxboro Massachusetts 02035 United States Details
Dana-Farber at Milford Milford Massachusetts 01757 United States Details
Dana-Farber at South Shore Hospital Weymouth Massachusetts 02190 United States Details
Montefiore Medical Center Bronx New York 10461 United States Details
UPMC Hillman Cancer Center - Arnold Palmer at Mountain View Greensburg Pennsylvania 15601 United States Details
UPMC Hillman Cancer Center - Arnold Palmer at Norwin Irwin Pennsylvania 15642 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213 United States Details
Baylor College of Medicine Medical Center Houston Texas 77030 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
University of Washington Fred Hutchinson Cancer Care Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field